Media stories about Boston Scientific Corporation (NYSE:BSX) have been trending positive on Friday, Alpha One Sentiment reports. The research firm, a service of Accern, identifies negative and positive news coverage by analyzing more than twenty million news and blog sources. Alpha One ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Boston Scientific Corporation earned a coverage optimism score of 0.30 on Alpha One’s scale. Alpha One also assigned news headlines about the medical equipment provider an impact score of 87 out of 100, meaning that recent news coverage is very likely to have an impact on the stock’s share price in the next few days.
Here are some of the news headlines that may have effected Alpha One’s rankings:
- Boston Scientific Corp. :BSX-US: Earnings Analysis: Q1, 2017 By the Numbers : June 16, 2017 (finance.yahoo.com)
- Wells Fargo & Company Reaffirms Outperform Rating for Boston Scientific Corporation (BSX) (americanbankingnews.com)
- Boston Scientific Up 27.5% Since SmarTrend Uptrend Call (BSX) (mysmartrend.com)
- Boston Scientific: We're always looking to add to portfol… (finance.yahoo.com)
- Boston Scientific Corporation — Moody’s assigns P-2 short term rating to Boston Scientific (finance.yahoo.com)
Boston Scientific Corporation (NYSE:BSX) remained flat at $27.75 during mid-day trading on Friday. The company had a trading volume of 8,520,683 shares. The stock has a market capitalization of $38.00 billion, a PE ratio of 88.94 and a beta of 1.05. The company’s 50-day moving average price is $26.98 and its 200 day moving average price is $24.54. Boston Scientific Corporation has a one year low of $19.67 and a one year high of $28.20.
Boston Scientific Corporation (NYSE:BSX) last released its earnings results on Thursday, April 27th. The medical equipment provider reported $0.29 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.30 by $0.01. The business had revenue of $2.16 billion for the quarter, compared to analyst estimates of $2.08 billion. Boston Scientific Corporation had a net margin of 5.07% and a return on equity of 23.45%. The business’s revenue for the quarter was up 10.0% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.28 earnings per share. Equities research analysts anticipate that Boston Scientific Corporation will post $1.25 earnings per share for the current year.
Several brokerages have weighed in on BSX. Needham & Company LLC reissued a “buy” rating and set a $29.00 price objective on shares of Boston Scientific Corporation in a report on Thursday, February 23rd. Northland Securities reissued a “positive” rating on shares of Boston Scientific Corporation in a report on Thursday, February 23rd. Oppenheimer Holdings, Inc. reissued a “hold” rating on shares of Boston Scientific Corporation in a report on Thursday, February 23rd. Zacks Investment Research raised shares of Boston Scientific Corporation from a “sell” rating to a “hold” rating in a report on Monday, April 24th. Finally, TheStreet lowered shares of Boston Scientific Corporation from a “b” rating to a “c+” rating in a report on Thursday, March 16th. Six investment analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and two have given a strong buy rating to the company’s stock. Boston Scientific Corporation has an average rating of “Buy” and a consensus target price of $28.36.
WARNING: This article was published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States & international copyright legislation. The original version of this article can be read at https://www.chaffeybreeze.com/2017/06/17/boston-scientific-bsx-receives-daily-coverage-optimism-score-of-0-30-updated-updated-updated.html.
In related news, SVP David A. Pierce sold 10,250 shares of the stock in a transaction that occurred on Wednesday, April 26th. The shares were sold at an average price of $26.00, for a total value of $266,500.00. Following the sale, the senior vice president now directly owns 35,850 shares in the company, valued at approximately $932,100. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Michael P. Phalen sold 79,045 shares of the stock in a transaction that occurred on Wednesday, March 29th. The shares were sold at an average price of $24.55, for a total transaction of $1,940,554.75. The disclosure for this sale can be found here. Insiders sold a total of 217,916 shares of company stock worth $5,606,540 over the last quarter. 0.74% of the stock is currently owned by corporate insiders.
About Boston Scientific Corporation
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.
Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with MarketBeat.com's FREE daily email newsletter.